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a b s t r a c t
Human immunodeﬁciency virus type 1 (HIV-1) transmission and infection occur mainly via the mucosal
surfaces. The commensal bacteria residing in these surfaces can potentially be employed as a vehicle for
delivering inhibitors to prevent HIV-1 infection. In this study, we have employed a bacteria-based strategy to
display a broadly neutralizing antibody VRC01, which could potentially be used to prevent HIV-1 infection.
The VRC01 antibody mimics CD4-binding to gp120 and has broadly neutralization activities against HIV-1. We
have designed a construct that can express the fusion peptide of the scFv-VRC01 antibody together with the
autotransporter β-barrel domain of IgAP gene from Neisseria gonorrhoeae, which enabled surface display of
the antibody molecule. Our results indicate that the scFv-VRC01 antibody molecule was displayed on the
surface of the bacteria as demonstrated by ﬂow cytometry and immunoﬂuorescence microscopy. The
engineered bacteria can capture HIV-1 particles via surface-binding and inhibit HIV-1 infection in cell culture.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The acquired immunodeﬁciency syndrome (AIDS) pandemic
caused by the human immunodeﬁciency virus type 1 (HIV-1) has
been ongoing for over three decades (Barre-Sinoussi et al., 1983;
Schupbach et al., 1984). It is estimated that 39 million people have
already died of AIDS-related diseases; 35 million people are living
with HIV-1, and 2.1 million people are newly infected each year
(UNAIDS, 2014). In spite of the recent optimism regarding a functional
cure for HIV-1, there are still substantial obstacles for achieving a
sterilizing cure with the current available treatment regimens. There-
fore, preventing new infection is still the priority for curbing the AIDS
epidemic. So far, much effort has been dedicated towards the
development of an effective AIDS vaccine, but none has yet been
successful (Burton et al., 2012; Johnston and Fauci, 2011; Lifson and
Haigwood, 2012; O’Connell et al., 2012; Xiang, 2013). Therefore, other
alternative prevention approaches are needed in order to curtail HIV-1
transmission and infection.
There are several reports on a new prevention approach using
gram-positive bacteria, such as lactobacilli, for surface display of CD4
(2-domains) (Liu et al., 2008), HIV-1 entry inhibitor cyanovirin-N (CV-
N) (Lagenaur et al., 2011; Liu et al., 2006; Yamamoto et al., 2013), or for
secretion of a CCR5 antagonist RANTES (Vangelista et al., 2010) and
HIV-1 fusion peptide inhibitors (Pusch et al., 2006) to prevent HIV-1
infection. These approaches involve the use of bacteria to synthesize
anti-HIV-1 inhibitors that can be secreted or displayed on the cell
surface so that the inhibitors can bind to the virus and prevent
infection. Since these commensal bacteria inhabit the mucosal sites
which are the port of entry for HIV-1, these protein-based inhibitors
can be produced by the bacteria which can be maintained as part of
the normal mucosal bacterial ﬂora, this approach could thus be
employed as a potential strategy to prevent HIV-1 infection.
Gram-negative bacteria have also been used for a number of
therapeutic applications including gene delivery into the gut
(Castagliuolo et al., 2005). Successful attempts include surface
display of lipase (Lee et al., 2013), antimicrobial peptides (Shin et
al., 2013), β-glucuronidase (Cheng et al., 2013) and also for the
secretion of single-chain or Fab antibody fragments (Cheung et al.,
1992; Fallecker et al., 2013; Fernandez et al., 2000). However, very
few studies have been reported in the use of gram-negative bacteria
as potential agents for the delivery (Abdel-Mohsen et al., 2013) of
anti-HIV regimens. So far only one study has been reported in
which Escherichia coli Nissle 1917 was used to secrete an anti-HIV-1
fusion peptide inhibitor to target gp41 glycoprotein of the virus.
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The fusion peptides from bacterial secretion can inhibit viral
infection in cell culture experiments, and bacterial colonization in
mice can last for weeks, or in some cases even months, however,
the viral challenge experiment in vivo has not yet been carried out
as the mice cannot directly be used for HIV-1 infection (Rao et al.,
2005). Surface display of anti-HIV-1 inhibitors on gram-negative
bacteria is another approach in this commensal bacterial strategy,
but it has not yet been tested. For surface display, the bacterial
transporter genes must be used to translocate the molecules of
interest onto the cell surface (Castagliuolo et al., 2005; Fairman et
al., 2011; Jose et al., 2012). Among the known transporters, the
autotranspoter (AT) is one of the most studied, and its structure and
translocating mechanisms have been reported recently (Benz and
Schmidt, 2011; Ieva and Bernstein, 2009; Rutherford and Mourez,
2006; van den Berg, 2010). More importantly, these autotranspor-
ters are shown to be able to translocate single-chain antibody
molecules onto the bacterial surface (Pyo et al., 2009; Veiga et al.,
1999, 2003).
In this report, we have used the gram-negative bacteria for
surface display of anti-HIV-1 antibody molecules. The autotranspor-
ter, an immunoglobulin A (IgA) protease gene (IgAP) of Neisseria
gonorrhoeae, was used because its C-terminal domain has been
shown to efﬁciently translocate the passenger domain at its N-
terminal (Dautin and Bernstein, 2007; Pohlner et al., 1987). We
therefore employed this gram-negative bacterial autotransporter
for surface display of a potent broadly neutralizing antibody
(VRC01) against HIV-1 infection. VRC01 is a potent neutralizing
antibody isolated from an HIV-1 patient, which can neutralize about
90% of HIV-1 isolates tested (Wu et al., 2010). VRC01 binds to the
CD4-binding site (CD4-BS) and can mimic CD4-binding to gp120
(Zhou et al., 2010). We have generated the single-chain variable
fragment (scFv) of VRC01 antibody (scFv-VRC01) and displayed it on
the surface of E. coli to test its ability to inhibit HIV-1 infection.
Results
Design of the scFv-VRC01 surface-display constructs
The scFv-VRC01 was designed using a two-step approach. The
ﬁrst was the designing of the single-chain (scFv) VRC01 antibody
domain for expression. The VRC01 antibody gene was used to
generate the single-chain antibody (scFv). A linker (-GGGGSG-
GGGSGGGGS-) was used to link the heavy chain (VH) and light
chain (VL) gene fragments. Two E-tags were inserted into the
recombinant gene; one was located between the β-barrel domain
and the single-chain antibody, another was added to the N-
terminus of the single-chain antibody (Fig. 1A). The resulting
recombinant protein would display the His-tag at the C-terminus
when expressed in the pET22b vector, and will be 257 amino acids
in length with an expected molecular weight of about 27 kDa. The
designed peptide was codon-optimized and synthesized for the E.
coli expression system. The second step was to link scFv-VRC01
fragment to the translocator β-barrel domain (C-IgAP) from
bacterial (N. gonorrhoeae) autotransporter (434aa), which will
then generate a fusion protein (scFv-VRC01-β-barrel domain (C-
IgAP)) of about 75 kDa. The proposed structural model of the
fusion recombinant protein molecule is shown in Fig. 1B. The scFv-
VRC01 fusion upon expression is then expected to be displayed on
the surface of the bacterial cell and bind to gp120 on the surface of
the HIV-1 virion to inhibit viral infection.
Expression of scFv-VRC01 antibody in E. coli
The synthesized single-chain VRC01 antibody (scFv-VRC01) gene
was ﬁrst cloned into the pET28b expression vector to test for
expression of the scFv-VRC01 protein with the predicted molecular
weight of about 27 kDa. As shown in Fig. 2A, a band of 27 kDa could
be detected in total bacterial lysates upon induction by IPTG, but
was absent in both un-induced lysates or in the supernatant of
induced samples. This suggests that the single-chain VRC01 anti-
body protein molecule could be expressed in E. coli, and found
mostly in the insoluble fractions of the bacterial lysates. The
recombinant protein was then further puriﬁed using the Ni-NTA
column and the presence of the protein was conﬁrmed by Western
blot analysis using anti-His-tag antibody. An example of the blot is
shown in Fig. 2B, conﬁrming that most of the expressed protein
could be found in the insoluble fraction of the bacterial lysate.
We then further characterized the expressed single-chain anti-
body VRC01 by determining whether it could be refolded into a
native conformation, and Far-Western blotting was used to analyze
whether it could bind gp120. This was carried out using anti-gp120
antibody to detect gp120 that was captured by the refolded scFv-
VRC01, and the result is shown in Fig. 2D. The gp120 molecule was
found to be bound by the refolded scFv-VRC01 on the membrane,
resulting in the presence of a 27 kDa band which corresponds with
expected size of the scFv-VRC01 antibody molecule and with the
size of puriﬁed scFV-VRC01 shown by Western blot analysis using
anti-His-tag antibody (Fig. 2C). Our results thus conﬁrmed that the
detected 27 kDa recombinant protein was indeed scFv-VRC01 and
when refolded, could bind gp120.
Inhibition of HIV-1 by the scFv-VRC01 antibody
Since the recombinant scFv-VRC01 can bind gp120 as deter-
mined by Far-Western blotting analysis, this suggested that the
refolded SCFV-VRC01 can possibly bind and neutralize HIV-1. We
then tested whether the expressed single-chain antibody VRC01
had neutralizing activity for different HIV-1 subtype strains. We tested
Fig. 1. Construction of fusion protein of single-chain antibody VRC01 and auto-
transporter β-domain from N. gornohoeae. (A) Schematic representation of the
fusion protein construct for surface display. Sp, signal peptide; E, E-tag; L, linker
(GSG); scFv, single-chain variable fragment; β-domain, the c-terminal part of
autotransporter serine proteinase gene of N. gornohoeae. H, His-tag. (B) Three
dimensional (3D) model of the fusion protein for surface display and its binding to
gp120. The linker is GSG plus the E-tag, β-barrel domain (PDB 1UYN (van den Berg,
2010)), scFV-VRC01 and gp120 of HIV-1 (PDB 3NGB).
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the activities of SCFv-VRC01 against two different HIV-1 subtypes,
subtype B (YU2) and subtype C (1084i), and the results are shown in
Fig. 3A. The sc-Fv-VRC01 was found to have neutralizing activity
against both HIV-1 strains. However, its activity was found to be
several folds lower than the full length VRC01 IgG (Fig. 3B). Ten mg/ml
of VRC01 was able to achieve 50% neutralization of 1084i but 50 μg/ml
of sc-Fv-VRC01 was needed to achieve similar levels of neutralization
(see Fig. 3A). This was not unexpected since a single-chain antibody is
generally known to be weaker than the full-length antibody in binding
activity.
Fig. 2. Expression and puriﬁcation of the designed single-chain antibody VRC01 in E. coli. (A) Polyacrylamide gel with Coomassie blue staining. Lane 1, cell pellet total
proteins of un-induced; 2, cell pellet total proteins of induced; 3, supernatant of cell lysate; 4, pellet of cell lysate; 5, Urea-solubilized inclusion bodies. (B) Western blot of the
same puriﬁed protein samples from A using anti-His-tag antibody. The speciﬁc band (27 kDa) of scFv antibody VRC01 is indicated by the arrow in (A and B). Western blot to
verify the puriﬁed single-chain antibody VRC01. (C) Western blot with anti-His-tag antibody. Lane1, gp120, 2, scFv_VRC01. (D) Far-Western blot ﬁrst with the binding of bait
protein gp120, then with the anti-gp120 antibody. Lane 1, BSA; 2, gp120, 3, scFv-VRC01. (E) Western blot of scFv-VRC01 and scFv-VRC01-β-domain fusion protein (75 kDa).
Both of the samples are labeled as follows: Lane 1, Supernatant of strain containing plasmid scFv-VRC01; 2, Supernatant of strain containing plasmid scFv-VRC01-β-domain;
3, Cell pellet of strain containing plasmid scFv-VRC01; 4, Cell pellet of strain containing plasmid scFv-VRC01-β-domain.
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Surface display of the scFv-VRC01 antibody on E. coli
In order to display the scFv-VRC01 on the bacterial surface, an
anchor protein domain (β-barrel domain) of IgAP from the auto-
transporter was added. The IgAP β-barrel domain can be inte-
grated into the outer membrane of the bacterial cell wall and will
translocate the N-terminal domain scFv-VRC01 from the cyto-
plasm to the cell surface. We then generated a construct (Fig. 1A
and B) that included the signal peptide (sp), the single-chain
antibody (scFv-VRC01), the anchor domain (C-IgAP) and the E-tag
for the detection. The induced bacterial lysate was tested for the
expression of the recombinant fusion protein by Western blot
analysis, and as expected a 75 kDa fusion protein was detected by
anti-E-tag antibody (Fig. 2E). To verify that this fusion protein
molecule could be displayed on the surface of the bacterium, ﬂow
cytometry was carried out to identify the presence of the recom-
binant scFv-VRC01 using FITC-conjugated rabbit anti-human IgG
antibody. Over 50% of the bacteria were shown to express scFv-
VRC01 on the cell surface (Fig. 4A).
To further conﬁrm the expression of the surface scFV-VRC01
confocal microscopy was carried out to directly visualize the
presence of the molecule on the bacterial surface using FITC
labelled antibodies. More than half of the cells were found to be
positive (Fig. 4B). The results corresponded well with the number
of positive cells determined by ﬂow cytometry analysis (Fig. 4A),
and suggest that the scFv-VRC01 molecules can be displayed on
the bacterial surface.
Binding and inhibition of HIV-1 infection by the bacterial displayed
scFv-VRC01
Since scFv-VRC01 could be expressed in a large number of
bacteria, it was important to determine whether they could bind
to HIV-1 and prevent its infection.
To demonstrate that the bacteria which displayed surface scFv-
VRC01 could adsorb viral particles, they were mixed with viral
particles (100 ml of 108/ml bacteria, and 12,500 RT units of HIV-1)
and the amount of unbound viral particles were determined by
measuring the residual RT (reverse transcriptase) activities in the
supernatant after binding. As shown in Fig. 5A, the presence of
bacteria expressing surface scFv-VRC01 could reduce the RT activity
in the supernatant by over 90% as compared to 60% non-speciﬁc
adsorption of the virion by control bacteria. The adsorption was
speciﬁc for HIV-1 since similar levels of inhibition were not observed
with MuLV control. As expected the scFv-VRC01 bacteria were found
to be equally effective against multiple strains of HIV-1 (Fig. 5A).
To further conﬁrm the effectiveness of the displayed scFc-VRC01
bacteria in inhibiting HIV-1 infection, infectivity assays using CF2-
Th cells were carried out. Following incubation of the virus with the
bacteria, the residual virus in the supernatant was used to infect
CF2-Th and the infectivity was determined by measuring luciferase
activity in the target cells. These results support the adsorption data
demonstrating that HIV-1 infectivity was reduced by over 90% after
incubation with the scFc-VRC01 bacteria, while much lower levels
of inhibition were observed with the control bacteria (Fig. 5B). Thus,
the bacterial cells with surface displayed scFv-VRC01 have the
ability to block HIV-1 infection in vitro.
Discussion
Using commensal bacteria as anti-HIV infection agents is a novel
initiative, and investigation in this area is still lacking with only very
few relevant published reports. In this report, we have demon-
strated as a proof of principle that the use of the β-domain of an
autotransporter is able to translocate a single-chain anti-HIV anti-
body molecule from the cytoplasm to efﬁciently display it on the
cell surface. The displayed molecule retained its anti-HIV activities
and was able to bind to different subtypes of HIV-1, however, our
expression system still needs to be optimized. Flow cytometry
analyses data showed that only about 53% of bacterial cells
positively displayed the scVRC01 on the cell surface. This suggests
that either some bacteria are either not expressing the recombinant
protein or their expression levels were below the detection limit.
Another possibility is that some of the bacteria might have lost the
plasmid upon passaging and propagation, or over expression of the
recombinant molecule could affect the bacterial viability, and only
certain bacteria with lower levels of expression had survived. These
issues will need to be further investigated since stable expression
and appropriate display are important factors contributing to the
success of this approach.
Another issue we encountered is the weaker neutralizing
activities by the single chain antibody compared to a full length
antibody, also indicated in a recent research paper that included
evalutions of several single-chain antibodies against HIV infection
including the scFv-VRC01 (West et al., 2012). This phenomenon is
actually well documented, single-chain antibody has weaker bind-
ing afﬁnity, and will result in weaker neutralizing activity when
compared to the native antibody molecule. As we know that the Fab
fragment antibody has a better afﬁnity than the single-chain anti-
body for binding to its antigen. Therefore, it will be signiﬁcant for us
to display the Fab fragment of the VRC01 antibody to increase the
neutralizing activity and improve this strategy for application.
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Fig. 3. Functional analysis of puriﬁed single-chain antibody VRC01.
(A) Neutralization assay of the scFv-VRC-1 against different strains of HIV-1: YU2
(subtype B), 1084i (subtype C). (B) Comparison of the scFv VRC01 antibody and
corresponding VRC01 IgG antibody.
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Nevertheless, our in vitro study here has shown that the use of
bacteria expressing anti-HIV inhibitors has the potential to be an
alternate approach for the prevention of HIV-1 infection. Following
this study and after the optimization of expression binding of the
antibody molecule, it will be necessary to deliver these engineered
bacteria into mice for colonization studies, examining how long the
bacteria can stay viable in the animals and how well the bacteria are
able to disseminate to different tissue sites. Further, it will be necessary
to test our system in an animal model, such as a humanized mouse or
the SHIV macaque model, for viral challenge experiments. This will
demonstrate the role and the efﬁcacy of the engineered bacteria in
preventing HIV-1 infection in vivo before testing any human trials.
Conclusions
This is the ﬁrst report of using gram-negative commensal
bacteria for surface display of anti-HIV single-chain antibody to
prevent HIV-1 infection. We have successfully displayed the
anti-HIV-1 single-chain antibody VRC01 on the surface of E. coli
bacteria and the engineered bacteria have shown neutralizing
activity in vitro. It is likely that this approach could be expanded to
be used in vivo as an alternative approach to prevent HIV-1
transmission and infection.
Materials and methods
Bacterial strains and vectors
E. coli K-12 strain DH5α, E. coli BL21 (λDE3) (Novagen) E. coli
K12 strain UT5600 (ΔompT) were used for surface display (Lum
and Morona, 2012; Maurer et al., 1997). pET22b, pET28b (Invitro-
gen) and PUC57 (GenScript) were used for cloning.
Fig. 4. Identiﬁcation of Surface display of fusion protein on E. coli. (A) Bacterial sample cells (E. coli) were treated with FITC-conjugated anti-rabbit IgG antibody and analyzed
by Flow cytometer. Orange, unstained bacterial cells as negative control; green, stained bacteria cells harboring the vector only; cyan, stained bacteria harboring the scFv-
VRC01-β-domain plasmid. The total gated positive cell percentage (M1) is shown in the ﬁgure. (B) Bacterial Cells displaying scFv-VRC01 on the surface using confocal
microscopy. The positive stained bacterial cells by FITC-conjugated anti-rabbit IgG antibody are shown in green. The same image is shown in (a) dark background window
(FITC). (b) the bright background window (FITC)þ(DIC) (differential interference contrast). The size bar showing in the picture is 5.0 m in (a) and 10.0 m in (b).
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Design of the single-chain antibody and fusion protein
The single-chain antibody VRC01 gene was designed using a
linker sequence (GGGGSGGGGSGGGGS) to connect the two domains
of antibody light chain (VH), and an E-tag fragment was added to the
N-terminus of the recombinant molecule to be used for detection of
protein expression. A 789-bp fragment with BamH1 and Xho1
restriction sites was synthesized by GenScript (Piscataway, NJ).
The 410 amino acids of the β-barrel domain (C-IgAP) fragment
were synthesized from the N. gonorrhoeae IgA1 protease gene of
C-terminal region from position 3364 to the end of the gene at
position 4599. An E-tag was added to the N-terminus, and a His-
tag was added to the end of the β-domain segment. The entire
1302 bp fragment was synthesized by GenScript.
The entire fusion protein consists of the signal peptide (sp),
scFV-VRC01, the β-domain (C-IgAP) plus the tags and linkers, which
total 2100 bp and encodes a peptide of 700 amino acids. The
structure of the recombinant gene and the predicted 3D structure of
the fusion protein are shown in Fig. 1A and B, respectively.
Expression and puriﬁcation of scFv-VRC01
The synthesized scFv-VRC01 gene fragment was removed from
the original vector pUC57 using the restriction enzymes BamH1
and Xhol, and then ligated into an E. coli expression vector pET28b
(Invitrogen). The vector containing scFv-VRC01 gene was trans-
formed into E. coli BL21 (λDE3) bacterial cells for protein expres-
sion. After transformation, the selected positive colonies were
cultured and induced by 0.5 mM IPTG (isopropylthio-β-galacto-
side) for 3 h at 37 1C. After induction, the cells were collected by
centrifugation and then disrupted by sonication. To purify the
protein from inclusion bodies, the precipitates were dissolved in
8 M urea and puriﬁed by Ni-NTA afﬁnity chromatography under
denaturing conditions. The protein was dialyzed for 24 h at 4 1C in
refolding buffer containing 50 mM Tris–HCl, 0.5 M L-Arginine,
50 mM NaCl and 10% glycerol. The protein concentration of
puriﬁed scFv-VRC01 protein was measured by BCA protein assay
(Pierce) and stored at 80 1C.
Surface expression of scFv-VRC01
The E. coli K-12 strain UT5600 was used as host cells for surface
display of the fusion protein. The designed β-domain(C-IgAP) gene
(1302 bp) was synthesized and cloned into the pUC57 vector
(GenScript). To construct the recombinant expression vector
pET22b-scFv-VRC01-β-domain(C-IgAP), the β-domain-E-tag encod-
ing fragment was cloned into the pET22b-scFv-VRC01 vector at the
Xhol site to generate the vector pET22b-scFv-VRC01-β-domain
which harbors the main fusion structure of scFv-VRC01, the
transporter C-terminal β-domain of IgAP and the E-tag connecting
the two fragments. Transformation of E. coli K-12 strain UT5600 was
performed as previously described (Lum and Morona, 2012; Maurer
et al., 1997). For induction of the fusion protein, single colonies were
picked and inoculated into liquid LB containing 2% (w/v) glucose
and antibiotics, and grown at 30 1C until OD600 was 0.5. Bacterial
cells were then harvested by centrifugation, resuspended into
similar volume of fresh liquid medium with antibiotics and
0.25 mM or 0.5 mM IPTG, and incubated further at 30 1C for 3 h.
To verify the expression of the scFv and β-domain of IgAP fusion
protein, 0.25 mM or 0.5 mM IPTG-induced E. coli cells containing the
vectors pET22b-scFv-VRC01-β-domain or control empty vector
pET22b were centrifuged and resuspended in 20 mM phosphate
buffer. The bacterial suspensions were mixed with 2 SDS sample
buffer. After 5 min of boiling, samples were brieﬂy centrifuged and
subjected to Western blot analysis. To verify that the fusion protein
was expressed in the insoluble fraction including membranes and
inclusion bodies, the bacterial cells, both before and after IPTG-
induction, were resuspended in PBS and sonicated at 15W for 30 s
5 times to break open the cells. After sonication the samples were
spun at 10,000 g for 20 min to pellet any unbroken cells or large
cellular debris. The supernatant was then centrifuged at 100,000 g
for 1 h at 4 1C to pellet the membrane, and then subjected to Western
blot analysis.
SDS-PAGE, Western blotting and far-Western blotting
Samples were run on a 10% SDS-polyacrylamide gel and stained
with Coomassie blue to verify protein expression.
For Western blotting analysis, the SDS-PAGE gel was further
transferred to a polyvinylidene ﬂuoride (PVDF) membrane (Millipore,
USA) and the membrane was blocked with blocking buffer (5% skim
milk in TBS) for 1 h at room temperature and reacted with primary
antibody (5000-fold diluted anti-His-tag antibody HRP conjugated
or 500-fold diluted rabbit anti-E-tag antibody) in blocking buffer for
16 h at 4 1C. The membrane was washed 3 times with wash buffer
(0.05% tween-20 in TBS) and incubated with a secondary antibody
(HRP conjugated anti-rabbit IgG antibody) for 1 h at room tem-
perature. After washing 3 times, the membrane was developed with
TMB membrane peroxidase substrate (KPL, USA). The anti-His-tag
antibody HRP conjugated (Abcam) or rabbit anti-E-tag antibody
HRP conjugated (Bioss Inc) was used for detection.
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Fig. 5. (A) Adsorption of HIV-1 particles by scFv-VRC01 surface displayed bacteria.
The engineered bacteria with the concentration of 108/ml mixed with the viral
stock can reduce the viral titer by surface binding. HIV-1 strains: YU2 (R5 virus,
subtype B), 1084i (R5 virus, subtype C), HXBc2 (X4 virus, subtype B), AMLV,
unrelated virus. RT, reverse transcriptase. (B) Inhibition of viral infection by scFv-
VRC01 surface displayed bacteria in vitro. The target cells (Cf2Th) stably expressed
receptor CD4 and co-receptor CCR5 were used for infection, and the luciferase was
a reporter gene. HIV-1 strains: YU2 (R5 virus, subtype B), 1084i (R5 virus, subtype C),
HXBc2 (X4 virus, subtype B) as negative control, AMLV, unrelated virus.
L.-X. Wang et al. / Virology 475 (2015) 179–186184
To examine the single-chain VRC01 antibody (scFV-VRC01) in the
fusion molecule, far-Western blotting was performed. BSA was used
as a negative control and HIV-1 gp120 was used as a positive control.
The puriﬁed scFv-VRC01 and the fusion protein containing scFV-
VRC01 were ﬁrst separated by SDS-PAGE and then transferred to
PVDF membrane. In order to refold the proteins on the membrane to
generate an intact binding site, a denaturation step was added. Brieﬂy,
immediately after transfer, the blot was incubated in 2% AC denatur-
ing buffers (100 mM NaCl, 20 mM Tris (pH 7.6), 0.5 mM EDTA, 10%
glycerol, 0.1% Tween-20, 2% skim milk powder and 1mM DTT) for
16 h at 4 1C, the membrane was then blocked in 5% skim milk and
incubated with 1:250 diluted gp120 in 2% AC buffer for 16 h at 4 1C.
The membrane was washed three times with wash buffer (0.05%
tween-20 in TBS) and incubated with HRP conjugated anti-gp120 for
1 h at room temperature. After washing three times, the membrane
was developed with TMBmembrane peroxidase substrate (KPL, USA).
Flow cytometry analysis
Bacteria were grown in the presence of IPTG as described above
until the log phase, 10 μl of each E. coli culture (106/ml bacteria)
containing the vectors pET22b-scFv-VRC01-β-domain(C-IgAP) or
empty vector pET22b were washed three times in PBS by centrifuga-
tion (10,000g for 15min) before theywere resuspended in 50 μl of PBS.
A 20-fold diluted rabbit anti-E-tag rabbit antibody conjugated with
Fluorescein isothiocyanate (FITC) (Bioss Inc) was added and the
samples were incubated for 1 h at 4 1C. The washing procedure in
PBS was repeated once and the samples were resuspended in 300 μl of
PBS. Bacterial ﬂow cytometry analysis was carried out with FACSCalibur
(Becton Dickinson) as described previously (Gunasekera et al., 2000).
Confocal microscopy
After growth in the presence of IPTG as described above, 10 μl of
each E. coli culture (106/ml bacteria) containing the vectors pET22b-
scFv-VRC01-β-domain or empty vector pET22b were washed 3 times
in PBS, spunned at 10,000g for 15 min before resuspending in 50 μl
of PBS. A 20-fold diluted rabbit anti-E-tag antibody conjugated-FITC
(Bioss, Inc) was added and the samples were incubated for 1 h at
4 1C. The washing procedure in PBS was repeated and the samples
were resuspended in 50 μl of 2% PFA in PBS. Images were collected
using a Leica TCS-NT/SP confocal microscope (Leica Microsystems,
Mannheim, Germany). Standard ﬁlters were used for FITC. The
detector slits for the FITC channel were conﬁgured to collect between
500 and 547 nm to minimize overlapping of the green and yellow
channels. All images were analyzed using the same gain, and
organized using the Adobe Photoshop (Adobe Systems, San Jose, CA).
Single-chain antibody neutralization assay
Cf2Th cells with CD4 and CCR5 receptors were used to test the
sensitivity of the viruses to neutralization by scFv-VRC01. 2500 RT
units of luciferase-expressing recombinant viruses were incubated
with 50 μg, 25 μg, 5 μg, and 0.5 μg, and 0.05 μg/ml of scFv-VRC01
in DMEM for 60 min at 37 1C. The virus–antibody mixtures were
then transferred to wells containing 105/well of target Cf2Th cells.
After overnight incubation, 0.1 ml of fresh medium was added to
each well, and the cells were cultured for 2 more days. The cells
were then lysed and assayed for luciferase activity (Tuner 20;
Promega). In another independent experiment, we compared the
neutralizing activity between scFv-VRC01 and the native IgG
VRC01 antibody (20 μg, 10 μg, 5 μg, and 0.5 μg/ml) using a sub-
type C HIV-1 recombinant luciferase-expressing virus 1084i.
Viral particles absorption assay
To determine the ability of E. coli expressing scFv-VRC01 on the
cell surface to bind HIV-1, the bacteria (100 ml of 108/ml) were
mixed with 12,500 RT units of viral stock (YU2, 1084i, HXBc2,
AMLV) and incubated with rocking for 1 h at 37 1C, then spun down
to remove the bacteria and RT was measured in the supernatant. RT
assay performed as described previously (Rho et al., 1981).
Bacteria neutralization assay
To determine the HIV neutralizing activity of E. coli expressing
scFv-VRC01 on the cell surface, the bacteria (100 ml of 108/ml) were
mixed with 2500 RT units of viral stock (YU2, 1084i, HXBc2, AMLV)
and incubated with rocking for 1 h at 37 1C, then spun down to
remove the bacteria. The supernatant was then transferred to
wells containing the target Cf2Th cells. The cells were then lysed
and assayed for luciferase activity. The luciferase activity assay was
performed as described previously (Xiang et al., 2002).
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